外周血造血干细胞移植后产生混合抗体1例

One case of multiple irregular antibodies produced after allogeneic hematopoietic stem cell transplantation

异基因造血干细胞移植（hematopoietic stem cell transplantation,HSCT）是一种治疗恶性血液病的有效手段,其中供受者ABO血型不合占30%-50%。虽然纯红细胞再生障碍（pure red cell aplasia,PRCA）和移植物抗宿主病（graft versus host disease,GVHD）与ABO和HLA的不合程度有关,但移植早期的预处理措施和免疫抑制剂的使用会大大削弱其影响。

Allogeneic hematopoietic stem cell transplantation （allo-HSCT） is an effective treatment for hematologic malignancies and 30 to 50 percent of allogeneic hematopoietic progenitor cell （HPC） transplants will involve ABO incompatible donor and recipients. Although pure red cell aplasia （PRCA） and graft versus host disease （GVHD） are concerned with ABO and HLA incompatibility, the affect will be weakened by preonditioning and immunosuppressive regiments in early period of HSCT. However, we observed a recipient who produced mul- tiple irregular antibodies during HSCT and finally died of hypoxic-ischemic encephalopathy （HIE） on day-u 119.